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Abstract 
The wild-type tumor suppressor protein ~53 is a short-lived protein that plays important roles in regulation of cell cycle, differentiation, and survival. 
Mutations that inactivate or alter the tumor suppressor activity of the protein seem to be the most common genetic change in human cancer and 
are frequently associated with changes in its stability. The ubiquitin system has been implicated in the degradation of ~53 both in vivo and in vitro. 
A mutant cell line that harbors a thermolabile ubiquitin-activating enzyme, El, fails to degrade p53 at the nonpermissive temperature. Studies in 
cell-free extracts have shown that covalent attachment of ubiquitin to the protein requires the three conjugating enzymes: El, a novel species of 
ubiquitin-carrier protein (ubiquitin-conjugating enzyme; UBC),EZ-Fl, and an ubiquitin-protein ligase, E3. Recognition of ~53 by the ligase is 
facilitated by formation of a complex between the protein and the human papillomavirus (HPV) oncoprotein E6. Therefore, the ligase has been 
designated E6-associated protein (E6-AP). However, these in vitro studies have not demonstrated that the conjugates serve as essential intermediates 
in the proteolytic process. In fact, in many cases, conjugation of ubiquitin to the target protein does not signal its degradation. Thus, it is essential 
to demonstrate that p53-ubiquitin adducts serve as essential proteolytic intermediates and are recognized and degraded by the 26s protease complex, 
the proteolytic arm of the ubiquitin pathway. In this study, we demonstrate that conjugates of ~53 generated in the presence of purified, El, E2. 
E6-AP, E6, ubiquitin and ATP, are specifically recognized by the 26s protease complex and degraded. In contrast, unconjugated ~53 remains stable. 
The ability to reconstitute the system from purified components will enable detailed analysis of the recognition process and the structural motifs 
involved in targeting the protein for degradation. 
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1. Introduction 
The tumor suppressor protein p53 is a short-lived pro- 
tein with a tX of - 20 min [ 11. Functionally, this instability 
probably reflects a requirement for rapid regulation of 
processes in which the protein plays a role. Structurally, 
it implies that the molecule contains signal(s) that target 
it for rapid degradation. Cumulative evidence indicates 
that the ubiquitin system is involved in the degradation 
of p53 both in vivo and in vitro. Utilizing a mutant cell 
line, ts20, that harbors most probably a thermolabile El, 
Chowdary and colleagues have shown that wt p53 is 
stabilized when the cells are shifted to the restrictive 
temperature. Following introduction of a cDNA clone 
that encodes El, degradation resumes [2]. Studies in 
reticulocyte lysates have demonstrated a role for the 
ubiquitin system in the degradation of p53 in a cell-free 
system. Immunodepletion of El resulted in a complete 
*Corresponding author. Fax: (972) (4) 51-3922 or (972) (4) 55-2296. 
Abbreviations: DEAE, diethylaminoethyl; DTT, dithiothreitol; El, 
ubiquitin-activating enzyme; E2, ubiquitin carrier protein or ubiquitin 
conjugating enzyme, UBC; E3, ubiquitin-protein ligase; E6, human 
papillomavirus ‘high-risk’ E6 16 oncoprotein; E6-AP, E6-associated 
protein; FPLC, fast protein liquid chromatography; HPV, human 
papillomavirus; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis; TCA, trichloroacetic acid. 
inhibition of proteolysis. The process resumed following 
addition of purified El to the system [3]. Werness and 
colleagues noted exceptionally low levels of p53 in 
human cervical carcinoma cell lines transformed by the 
‘high risk’ HPVs- 16 and - 18. They demonstrated that the 
E6 proteins of the ‘high risk’ but not the ‘low risk’ HPVs 
associate with p53 in vitro [4]. They tested the hypothesis 
that, unlike other complexes that p53 forms and that lead 
to stabilization of the protein, HPV E6s target the pro- 
tein for degradation. Such a mechanism could explain, 
at least in part, the tumorigenicity of these oncoproteins. 
Indeed, the ‘high risk’ E6 proteins stimulate ATP- 
dependent conjugation and degradation of p53 in crude 
reticulocyte lysates [5]. There is a clear correlation be- 
tween the ability of different p53 species to associate with 
E6 and their sensitivity to proteolysis. For example, 
human p53-Thr 232 does not associate with E6 and is 
relatively stable in the cell-free proteolytic system. In 
contrast, p53-His273 binds strongly to E6 and is degraded 
efficiently [6]. The mechanism(s) of targeting of p53 by 
E6 is not known. It was noted that E6 remains stable 
throughout the proteolytic cycle. It is possible that E6 is 
recognized by the ubiquitin-protein ligase, but cannot be 
targeted as it does not have accessible ubiquitination 
sites (see below). In contrast, p53 cannot bind to the 
ligase, but it harbors Lys residues that can be readily 
conjugated. Similar tram recognition and targeting have 
0014-5793/94/$7.00 0 1994 Federation of European Biochemical Societies. All rights reserved. 
SSDI 0014-5793(94)00582-G 
D. Shkedy et al. IFEBS Letters 348 (1994) 126-130 127 
been demonstrated in the degradation of other proteins 
as well. A fusion protein between the N-terminal half of 
the HPV-16 E7 protein and the full-length HPV-16 E6, 
promoted the in vitro degradation of the retinoblastoma 
protein [7]. The E7 protein harbors the retinoblastoma 
binding site, whereas the E6, most probably, binds to the 
ubiquitin ligase and thus confers the proteolytic sensitiv- 
ity. In a different case, Johnson and colleagues have 
shown that in a heterodimeric protein, the N-terminal 
residue that serves as the ligase-binding site and the Lys 
residue that is targeted by ubiquitin, can reside in differ- 
ent subunits of the protein [8]. In this case, only the 
ubiquitinable subunit is degraded. Recently, two addi- 
tional factors involved in the conjugation of p53 have 
been purified and characterized. We have shown that a 
novel species of E2 is required for conjugation and deg- 
radation of p53 [9]. Unlike most members of the E2 
family, this enzyme does not adsorb to anion exchange 
resin in neutral pH and it is purified from the unadsorbed 
material (Fraction 1; see below). Thus it was designated 
E2-Fl [lo]. The enzyme is not specific to p53 and is 
involved in the degradation of a variety of cellular sub- 
strates. Interestingly, it recognizes non-‘N-end rule’ pro- 
tein substrates uch a glyceraldehyde-3-phosphate d hy- 
drogenase (Val at the N-terminal position; [lo]). Scheff- 
ner and colleagues have described what appears to be a 
similar enzyme [l 11. These researchers have also shown 
that the E6-p53 complex binds to a cellular protein of 
100 kDa, designated E6-AP. Formation of this ternary 
complex leads to rapid ubiquitination and subsequent 
degradation of the protein. In all these studies, research- 
ers have purified and characterized the components in- 
volved in conjugation of ubiquitin to ~53. However, it 
has not been shown that the conjugates erve indeed as 
essential intermediates in the process: modification of 
proteins by ubiquitin can serve nonproteolytic functions 
as well [12]. Furthermore, it has not been shown that the 
26s protease complex, the protease that recognizes and 
degrades ubiquitin-modified proteins, plays a role in the 
process. These two unresolved problems have been in- 
vestigated in the present study. 
2. Experimental procedures 
2. I. Materials 
cDNAs encoding murine wt p53 and HPV-16 E6 were subcloned into 
pSP64 and pGEM-2 transcription vectors as described [9]. cDNA that 
encodes a truncated 75 kDa form of E6-AP constructed into the bacte- 
rial expression vector pGEX-2TK vector [ll] was obtained from Dr. 
Martin Scheffner, DKFZ, Heidelberg, Germany. A recombinant bacu- 
lovirus expressing the 95 kDa form of E6-AP [ 131 was obtained from 
Drs. Jon M. Huibregtse and Peter M. Howley, Harvard Medical 
School, Boston, MA, USA. Wheat germ extract for in vitro translation 
was from Promega. All restriction enzymes used were from New Eng- 
land Biolabs. Centricon 30 microconcentrators were from Amicon. 
Rainbow prestained molecular weight markers were from Amersham. 
L-l?S]Methionine (- 1,200 Wmmol) and Enlizhtnine enhancer were 
from-DuPont-New’England Nuclear. All othermategals and reagents 
were as described [9]. 
2.2. Methods 
Subcloning of cDNAs and synthesis ojmRNAs and labeled proteins. 
All manipulations of plasmids (such as transformations, purification, 
and restriction analyses) were carried out as described [14]. Synthesis 
of mRNAs of p53 and E6 from the corresponding cDNAs was carried 
out as described [9,14] using the appropriate RNA polymerases. 
mRNA was translated in vitro in the presence of [“Slmethionine (p53) 
or unlabeled methionine (E6) except hat wheat germ extract was used 
instead of rabbit reticulocyte lysate. Unlike the mammalian cells, the 
plant cells do not contain E6-AP [11,13]. This selective development 
enables a relatively easy purification of the labeled protein and monitor- 
ing its conjugation and degradation following addition of exogenous 
purified enzyme. Following synthesis, the proteins were further purified 
using anion exchange chromatography as described [3,9]. 
Preparation ojE1. E2-FI, E6-AE: and 26Sprotease complex. Reticu- 
locyte-rich blood was induced in rabbits by successive injections of 
phenylhydrazine, and reticulocyte lysates were prepared as described 
[15]. Following depletion of ATP, lysates were resolved by anion ex- 
change chromatography on DEAE-cellulose into tmadsorbed material 
(Fraction 1) and high salt eluate (Fraction 2) as described [15]. El was 
purified to homogeneity from Fraction 2 following ‘covalent’ affmity 
chromatography over immobilized ubiquitin as described [15]. E2-Fl 
was purified to homogeneity from Fraction 1 as described [lo]. E6-AP 
was purified from three independent sources: (a) glutathione-trans- 
ferase-E6-AP fusion protein was purified using affinity chromatogra- 
phy over immobilized glutathione [l 11; (b) using anion exchange chrom- 
atography over Mono-Q FPLC column, E6-AP was partially purified 
from Sf9 cells following infection with a recombinant virus exnressing 
the protein; (c) the enzyme was partially purified from reti&locyte 
Fraction 2 by (NH&SO., precipitation (&38%) and gel filtration 
chromatography over Superdex 200 HR (16 x 600 mm) column. 8 mg 
of protein-were loaded onto the column and the proteins were resolved 
in a buffer that contained 20 mM Tris-HCl, pH 7.2, 150 mM NaCl, and 
1 mM DTT. Fractions of 2.4 ml were collected. The samples were 
concentrated to 200 ~1 and the buffer was rapidly changed to a similar 
buffer that does not contain salt by repeated concentrationdilution 
cycles using Centricon 30 microconcentrators. Although all three forms 
of the ligase are active in conjugation of ubiquitin to ~53, the bacterially 
expressed truncated enzyme has a relatively low specific activity. There- 
fore, in order to generate sufficiently large amount of degradable ad- 
ducts, we used either the baculovirus expressed or the reticulocyte- 
based enzyme. The reticulocyte nzyme was used in most assays as it 
is more readily available. The 26s protease complex was purified to 
homogeneity as described [16]. 
Reconstitution of proteolysis of ~53 by purified components of the 
ubiquitin system. A complete reaction mixture contained in a final 
volume of 25 ~1: 0.5 fig El, 0.15pg E2-Fl, 3.Opg E6-AP, - 20,000 cpm 
~53 (- 1 ng; 9). 0.5 ul E6 (- 1.8 nz: 6-fold the molar amount of ~53; 9), 
1.5 ig 26s protease complex, 116 pg ubiquitin, 2 mM ATP,‘5 mM 
MgCl,, 2.5 mM NH,COOH, 2 mM DTT, and 40 mM Tris-HCl, pH 
7.6. Degradation i crude reticulocyte lysate was monitored in a similar 
reaction mixture in which the enzymes (El, E2-Fl, E6-AP and the 26s 
protease) were substituted for 10 ~1 of crude reticulocyte lysate. In 
addition, the mixture also contained creatine kinase and phos- 
phocreatine (for regeneration of ATP) as described [9]. Following incu- 
bation at 30°C for 3 h, degradation of the [35S]methionine-labeled 
protein was determined by monitoring the radioactivity released into 
trichloroacetic acid (TCA)-soluble fraction as described [3,9]. In all 
cases, two sets of reactions were incubated, one contained ATP and the 
other contained hexokinase (0.5 pg) and 2-deoxyglucose (10 mM). 
Degradation values in systems from which ATP was depleted did not 
exceed 20% of the values obtained in the presence of ATP. These values 
were subtracted and results are presented as net ATP-dependent degra- 
dation (% of total protein degraded). 
Formation and degradation ojubiquitiwp53 conjugates. Ubiquitin-p53 
conjugates were generated in a 200 ~1 reaction mixture that contained: 
4.0pgE1, 1.2~g~E2-Fl, 24.0pgE&AP, -200,000cpmp53,4.0~1 E6, 
10.0 fig ubiquitin, 2 mM ATP, 5 mM MgCl,, 2.5 mM NH,COOH, 
2 mM DTT, and 40 mM Tris-HCl, pH 7.6. Following incubation for 
1 h at 3O”C, 10 ~1 of 2 N NaOH was added and the incubation 
continued for additional 10 min at 30°C. The base was neutralized by 
the addition of 9pl of 2 N HCl (to a final pH of- 8-9) and the conjugates 
were stored at 4°C. The mixture contained conjugated p53 as well as 
unreacted protein. However, it did not contain any active conjugating 
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enzyme: the enzymes were inactivated by NaOH. To study the effect 
of the 26s protease complex on unconjugated ~53, we incubated p53 
in a similar reaction mixture that did not contain the conjugating 
enzymes, E6, ubiquitin and ATP. Quantitative analysis revealed that 
37% of the labeled protein was shifted to high molecular mass ubiquitin 
adducts. To follow the partial purification of E6-AP, we also monitored 
formation of conjugates. In this case, the reaction mixture contained 
in a final volume of 25 ~1: 0.5 pug El, 0.15 pg E2-Fl, 2.0 ~1 of the 
Superdex 200 HR column (as a source for E6-AP; see above), - 10,000 
cpm p53,0.5 ~1 E6,2.0 pg ubiquitin, 1 pg ubiquitin aldehyde, a specific 
inhibitor of certain isopeptidases [17], 5 mM ATPyS, 5 mM MgClr, 2.5 
mM NH,COOH, 2 mM DTT, and 40 mM Tris-HCI, pH 7.6. Degrada- 
tion of conjugates or free p53 by the purified 26s protease was moni- 
tored in a reaction mixture that contained in a final volume of 25 ~1: 
- 10,000 cpm p53-ubiquitin conjugates-free p53 mixture or free ~53, 1.5 
fig 26s protease complex, 5 mM ATP (or a system without ATP), 5 mM 
MgCl,, 2.5 mM NH,COOH, 2 mM DTT, and 40 mM Tris-HCI, pH 
7.6. Following incubation at 30°C for 3 h, degradation of the 
[35S]methionine-labeled protein was determined by measuring the radi- 
oactivity released into TCA-soluble fraction as described above. For- 
mation and degradation of conjugates were also monitored by SDS- 
PAGE (10%) [18] followed by fluorography as described [9]. 
3. Results 
3.1. Purification of E6-Ae the ubiquitin-protein ligase 
involved in conjugation of p53 
Whereas El and E2-Fl, the two first enzymes in the 
conjugation process, have been purified to homogeneity, 
the E3 involved in the process, E6-AP, is not available 
in large enough amounts to enable one to carry out 
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reconstitution of the complete proteolytic system. Ini- 
tially, we utilized a truncated recombinant form that 
lacks the N-terminal domain of the enzyme [l 11. The 
enzyme is expressed as a fusion protein with glutathione 
transferase and has been purified via affinity chromatog- 
raphy over immobilized glutathione. The enzyme is ac- 
tive; however, the specific activity is extremely low and 
does not allow formation of large amounts of conjugates 
that can serve as substrates to the 26s protease complex 
(not shown). The low activity is probably due to the fact 
that the protein is not complete. Trials to express the 
protein from full-length cDNA have failed (J.M. 
Huibregtse, M. Scheffner, and P.M. Howley, unpub- 
lished results). Therefore, we have partially purified an 
intact enzyme from either Sfp cells that express a recom- 
binant virus containing the enzyme, or from a native 
source, reticulocyte lysates. Both enzymes were similarly 
active, and the assays presented in this study have been 
performed using the reticulocyte enzyme. Fig. 1 demon- 
strates the last purification step, gel filtration chromatog- 
raphy over Superdex 200 HR FPLC column. Fractions 
27-29 were pooled and served a source for the enzyme. 
3.2. Reconstitution of degradation of p53 from purljied 
components of the ubiquitin proteolytic system 
Following purification of all the enzymatic compo- 
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Fig. 1. E6-AP activity: gel liltration chromatography of ammonium sulfate-fractionated Fraction 2. Monitoring of E6-AP activity was carried out 
in the presence of purified El, E2-Fl, E6, ubiquitin, and ATP in fractions resolved on a Superdex 200 FPLC column as described in section 2. Lane 
A = p53 substrate; lane B = reaction carried out in the presence of 10 pg unresolved extract; Lanes 1637 = activity in fractions 1637; lanes 
39/4&47/48 = activity in the corresponding paired pooled fractions. D.B. = elution of dextran blue; 240, 68 and 12.5 = elution of catalase, bovine 
serum albumin, and cytochrome c, respectively. Molecular weight markers are: 200.0 = myosin; 69.0 = bovine serum albumin; 46.0 = ovalbumin; 
30.0 = carbonic anhydrase; 21.5 = soybean trypsin inhibitor; 14.3 = lysozyme. Ori. denotes origin of gel; Conj. denote conjugates; D.F. denotes dye 
front. Labeled p53 is marked. 











Fig. 2. Formation of p53-ubiquitin conjugates. Conjugates were gener- 
ated as described in section 2. Lane 1 = reaction mixture was incubated 
without the conjugating enzymes, E6, ubiquitin and ATP, lane 
2 = complete reaction mixture. Molecular weight markers are as de- 
scribed in the legend to Fig. 1, except that 97.4 is phosphorylase b. 
Other marks are as described in the legend to Fig. 1. 
tant to demonstrate that degradation can be reconsti- 
tuted following addition of all the components to the 
reaction mixture. As can be seen from Table 1, this is 
indeed the case. It should be noted that omission of El 
does not inhibit the reaction completely. This is probably 
due to the fact that the purified preparations of p53 and 
E6, that are derived from wheat germ extract, contain a 
small amount of the enzyme. El is an extremely active 
enzyme and small amounts that have not been removed 
can explain activity in such extracts. Also noted is the 
activity obtained in the absence of E6. We have noted 
already [3,9] that ATP- and ubiquitin-dependent degra- 
dation proceeds also in the absence of the viral oncopro- 
tein, though at a lower rate. This is not surprising, as wt 
~53 is short-lived in all cells studied, most of them do not 
Table 1 
Reconstitution of degradation of p53 from purified components of the 
ubiquitin proteolytic pathway 
Components of system Degradation (%) 
Complete system 9.3 
Complete system - El 3.2 
Complete system - E2-Fl 0.0 
Complete system - EG-AP 0.0 
Complete system - E6 2.6 
Complete system - 26s protease 0.0 
Reticulocyte lysate 21.3 
Degradation in the various reconstituted systems and in crude reticulo- 
cyte lysate was monitored as described in section 2. 
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contain E6. An important finding relates to the role of 
the 26s protease complex in the proteolytic process: in 
this experiment it has been demonstrated clearly that the 
protease serves an essential role. 
3.3. The 26s protease complex degrades preformed 
p53-ubiquitin conjugates but not free ~53 
To demonstrate the intermediacy of p53-ubiquitin ad- 
ducts in the proteolytic process, we have first generated 
large enough amounts of high molecular mass adducts. 
These are demonstrated in Fig. 2. It is clear that the 
adducts are generated from ~53, as loading of equal 
amounts of radioactivity on the gel demonstrates reduc- 
tion in the amount of free ~53 with a concomitant in- 
crease in the amount of the conjugates formed (Fig. 2, 
compare lane 1 to lane 2). These conjugates were sub- 
jected to proteolysis by purified 26s protease complex. 
As can be clearly seen from Table 2, the conjugates are 
degraded in an ATP~e~ndent mode. This finding rules 
out the possibility that the 20s protease can also recog- 















Fig. 3. Degradation of p53-ubiquitin conjugates by puritied 26s pro- 
tease complex. Degradation of conjugates was monitored as deseribed 
in section 2. Lane A = unreacted ~53; lane 1 = reaction mixture without 
protease complex; lane 2 = with 0.75 pug 26s complex; lane 3 = with 1.5 
pg 26s complex. All other marks are as described in the legend to 
Fig. 1. F.D. denotes front of dye. 
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require energy. In contrast, unconjugated ~53 is not rec- 
ognized and degraded. Fig. 3 demonstrates imilar find- 
ings. Interestingly, certain amount of the intact protein 
is regenerated (compare lane 1 to lanes 2 and 3). This is 
probably due to the activity of isopeptidase(s) that is an 
integral part of the complex. Such an isopeptidase has 
been described [19], though, the p53-regenerating activ- 
ity is not necessarily the same as the one described. 
4. Discussion 
We have shown that degradation of ~53 can be recon- 
stituted from purified components of the ubiquitin prote- 
olytic system. The study clearly demonstrates that ubiq- 
uitin protein conjugates serve as essential intermediates 
in the proteolytic process and that the free protein cannot 
be degraded. Furthermore, it shows, for the first time, 
that the 26s protease is involved in recognition of the 
conjugates and in their degradation. It should be noted, 
however, that degradation in crude reticulocyte lysate is 
more efficient. It may be that in the crude extract the 
different components act more efficiently. For example, 
they may associate with one another to form multien- 
zyme complexes that can process the substrate in a 
processive manner. An alternative xplanation is that the 
system is still not complete and additional auxiliary fac- 
tors are still missing. Hadari and colleagues have re- 
cently described an isopeptidase (Iso-T) that stimulates 
degradation of several factors [20]. Gonen and col- 
leagues have demonstrated that a specific factor is re- 
quired for the degradation of several N-terminal blocked 
proteins (FH) [16]. Both factors act along with the 26s 
protease complex to stimulate degradation of ubiquitin- 
modified substrates. Addition of purified Iso-T and FH 
to both complete system and the 26s protease did not 
stimulate further degradation. It may well be that other 
factors, the requirement of which is not obvious from our 
current understanding of the system, also play a role in 
the process. These can be, for example, molecular 
chaperones that present he substrate in a proper confor- 
mation for either conjugation or degradation. Establish- 
Table 2 
Degradation of ubiquitin-p53 adducts and free unconjugated p53 by 
purified 26s protease complex 
Substrate System Degradation (%) 
P53 -ATP 0.9 
+ATP 2.7 
p53-Ub -ATP 4.1 
+ATP 35.6 
Degradation of free p53 and ubiquitinp53 conjugates was monitored 
following release of radioactivity to the TCA-soluble fraction as de- 
scribed in section 2. As the preparation of conjugates contain also free 
unreacted ~53, results were corrected to reflect the proportion of radi- 
oactivity in the conjugates. 
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ment of a cell-free proteolytic system can promote isola- 
tion of such putative factors. Such systems can also serve 
as useful tools in analyzing the mechanism of action of 
the ubiquitin system. For example, the mechanistic basis 
for the role of E6 as a tram recognition element can now 
be studied. As explained above, E6 may harbor the ligase 
binding domain but does not have a ubiquitinable Lys 
residue, whereas ~53 which cannot bind directly to the 
ligase, binds via E6 and is ubiquitinated at specific Lys 
residues and degraded. This model can now be tested 
experimentally in the reconstituted system. 
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